← All indications
Acute Disease
Disease having a short and relatively severe course.
Drugs by status
Phase 4 trials (3)
Phase 3 trials (3)
Phase 2 trials (1)
Organizations
Organization Involved with Phase 4 Indications (27)
- Eisai
- Sanofi
- Bayer
- Qingfeng Pharmaceutical Group
- bene-Arzneimittel GmbH
- Ahn-Gook Pharmaceuticals Co.,Ltd
- Jordi Gol i Gurina Foundation
- Changhai Hospital
- Gottfried Wilhelm Leibniz Universität Hannover
- Guangzhou Medical University
- Johns Hopkins University
- Sichuan University
- University of Bologna
- Nanchang University
- Gannan Medical University
- Jiujiang First People's Hospital
- First Hospital of Shijiazhuang City
- Jiao Tong University
- Medaimun GmbH
- Catholic University of Korea
- Janssen Pharmaceutica NV
- University of Alabama, Birmingham
- University of Brescia
- Catalan Institute of Health
- Spanish Clinical Research Network
- Johnson and Johnson
- University of Helsinki
Organization Involved with Phase 3 Indications (31)
- Abbott
- Actinium Pharmaceuticals
- The Medicines Company
- Millennium Pharmaceuticals
- Centocor
- Eli Lilly
- Pfizer
- Novartis
- INC Research
- MolMed S.p.A.
- Daewon Pharmaceutical Co., Ltd.
- Replidyne
- National Cancer Institute (NCI)
- Central South University
- King Faisal University
- McMaster University
- Chonbuk National University
- Laval University
- Peking University
- University of British Columbia
- University of Calgary
- All India Institute of Medical Sciences
- First People's Hospital of Chenzhou
- King Faisal Specialist Hospital
- Southern Medical University
- Sun Yat-Sen University
- University of Montreal
- Universidad Autonoma de Barcelona
- Vita-Salute University of Milano. Italy
- University of Genoa
- +1 more
Organization Involved with Phase 2 Indications (34)
- Abgenix
- Astellas
- AstraZeneca
- Zambon
- Hanlim Pharm. Co., Ltd.
- Ionis Pharmaceuticals, Inc.
- North China Pharmaceutical Group Corporation
- PharmaKing
- Prescient Therapeutics, Ltd.
- Syndax Pharmaceuticals
- Sunesis Pharmaceuticals
- Boehringer Ingelheim
- National Institutes of Health (NIH)
- University of Washington
- Seoul National University
- Universidad Autonoma de Madrid
- Universidad Complutense de Madrid
- Thomas Jefferson University
- University of Michigan
- University of South Florida
- Wake Forest University
- University of Ulsan
- National Taiwan University
- Korea Pharmaceutical Manufacturers Association
- City of Hope National Medical Center
- University of Texas at Houston
- Daejeon University
- Technical University of Dresden
- J. W. Goethe University
- 3201 Hospital of Hanzhong
- +4 more
Organization Involved with Phase 1 Indications (26)
- Spectrum Pharmaceuticals
- Ambit Biosciences
- Celgene
- Enzon
- Genzyme
- PharmaMar
- Emory University
- Institut Paoli-Calmettes
- Medical College of Wisconsin
- New York University
- Shenzhen Geno-Immune Medical Institute
- Southwest Oncology Group
- University of Miami
- University of Southern California
- Tel Aviv University
- University of California, Davis
- National University of Singapore
- Gateway for Cancer Research
- The Leukemia and Lymphoma Society
- Alex's Lemonade Stand Foundation
- Pediatric Oncology Experimental Therapeutics Investigation Consortium
- Ono Pharmaceuticals
- Shantou University
- GenScript
- Inatherys
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Organization Involved with Other Experimental Indications (18)
- Dey
- Kaiser Permanente
- Rhode Island Hospital
- Seinajoki Central Hospital
- University of Oulu
- University of Tampere
- Yonsei University
- University of Turku
- University of Minnesota
- Kuopio University Hospital
- Memorial Clinical Reasearch, OK
- Mercy Medical Group
- Government of Finland
- Mikkeli Central Hospital
- Children's Cancer Research Fund United States
- Government of Hong Kong
- China Medical University
- Jyväskylä Central Hospital